ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Thursday, August 7th. The company reported earnings of $0.25 per share, beating estimates of $0.20 by $0.05. The company also reported revenue of $362,240,000, beating estimates of $296,257,602 by $65,982,398.
You can see Quiver Quantitative's $ARRY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARRAY BIOPHARMA Hedge Fund Activity
We have seen 111 institutional investors add shares of ARRAY BIOPHARMA stock to their portfolio, and 128 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 4,452,512 shares (-66.0%) from their portfolio in Q1 2025, for an estimated $21,683,733
- CITADEL ADVISORS LLC added 3,945,869 shares (+6873.3%) to their portfolio in Q1 2025, for an estimated $19,216,382
- SWEDBANK AB removed 3,553,300 shares (-86.7%) from their portfolio in Q2 2025, for an estimated $20,964,470
- PECONIC PARTNERS LLC added 2,400,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $11,688,000
- POINT72 ASSET MANAGEMENT, L.P. removed 2,267,130 shares (-65.4%) from their portfolio in Q1 2025, for an estimated $11,040,923
- PACER ADVISORS, INC. added 1,760,250 shares (+inf%) to their portfolio in Q1 2025, for an estimated $8,572,417
- INVENOMIC CAPITAL MANAGEMENT LP removed 1,730,203 shares (-89.5%) from their portfolio in Q1 2025, for an estimated $8,426,088
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARRAY BIOPHARMA Analyst Ratings
Wall Street analysts have issued reports on $ARRY in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 06/20/2025
- Jefferies issued a "Buy" rating on 05/20/2025
- Goldman Sachs issued a "Buy" rating on 05/19/2025
- Guggenheim issued a "Buy" rating on 05/16/2025
- UBS issued a "Buy" rating on 05/08/2025
- Truist Securities issued a "Buy" rating on 04/17/2025
- Barclays issued a "Overweight" rating on 03/06/2025
To track analyst ratings and price targets for ARRAY BIOPHARMA, check out Quiver Quantitative's $ARRY forecast page.
ARRAY BIOPHARMA Price Targets
Multiple analysts have issued price targets for $ARRY recently. We have seen 13 analysts offer price targets for $ARRY in the last 6 months, with a median target of $8.5.
Here are some recent targets:
- Biju Perincheril from Susquehanna set a target price of $7.5 on 07/21/2025
- Maheep Mandloi from Mizuho set a target price of $9.0 on 06/27/2025
- Paul Coster from JP Morgan set a target price of $13.0 on 06/20/2025
- Michael Blum from Wells Fargo set a target price of $8.0 on 06/20/2025
- Julien Dumoulin-Smith from Jefferies set a target price of $10.0 on 05/20/2025
- Brian Lee from Goldman Sachs set a target price of $11.0 on 05/19/2025
- Joseph Osha from Guggenheim set a target price of $12.0 on 05/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
